Should a 66-year-old patient with anxiety, normal laboratory studies, college education, and a Saint Louis University Mental Status (SLUMS) score of 14 be referred to a memory clinic, also seen by a neurologist, and started on donepezil?

Management of Cognitive Impairment with SLUMS Score of 14

Do not start donepezil at this time—first complete a comprehensive diagnostic workup including memory clinic and neurology evaluation to establish a definitive diagnosis, as cholinesterase inhibitors are only indicated for confirmed Alzheimer's disease, not for undifferentiated cognitive impairment. 1, 2

Understanding the SLUMS Score of 14

A SLUMS score of 14 in a college-educated patient indicates severe cognitive impairment and falls well below the threshold for dementia:

• For individuals with high school education or greater, scores ≤20 suggest dementia 3, 4
• A score of 14 is approximately 6 points below the dementia cutoff, indicating substantial cognitive dysfunction 3
• This score suggests possible dementia rather than mild cognitive impairment (MCI), which typically scores 21-26 in educated individuals 4

Critical Diagnostic Steps Before Treatment

Why Diagnosis Must Precede Treatment

Cholinesterase inhibitors like donepezil are FDA-approved only for diagnosed Alzheimer's disease (mild to moderate severity), not for undifferentiated cognitive impairment or screening test abnormalities alone. 5

The current clinical picture presents several diagnostic uncertainties:

• Anxiety as a confounding factor: Anxiety can significantly impair cognitive test performance and may mimic or exacerbate cognitive symptoms 6, 7
• Normal laboratory studies: While reassuring, these do not establish the etiology of cognitive impairment
• Single screening test: The SLUMS is a screening tool, not a diagnostic instrument—it identifies who needs further evaluation but cannot diagnose dementia etiology 8, 3

Recommended Referral Strategy

Both memory clinic AND neurology referrals are appropriate and complementary:

Memory Clinic Referral (Priority):

• Provides comprehensive neuropsychological testing to confirm cognitive impairment severity and pattern 8
• Distinguishes between Alzheimer's disease, vascular dementia, frontotemporal dementia, and other etiologies 8
• Evaluates whether anxiety or depression contributes to cognitive symptoms 7
• Establishes baseline cognitive profile for monitoring progression 8

Neurology Referral (Concurrent or Sequential):

• Rules out reversible causes (normal pressure hydrocephalus, subdural hematoma, brain tumor) 1
• Obtains structural brain imaging (MRI preferred) to assess for vascular disease, atrophy patterns, and structural lesions 1
• May order additional biomarker testing (CSF analysis, amyloid PET) if diagnosis remains uncertain 9
• Evaluates for non-Alzheimer's neurodegenerative conditions (Lewy body dementia, Parkinson's disease dementia) 1

When to Consider Donepezil

Appropriate Timing for Initiation

Start donepezil only after:

1. Confirmed diagnosis of Alzheimer's disease through comprehensive evaluation 1, 2
2. Severity classification as mild to moderate (MMSE 10-26 or equivalent) 1, 5
3. Discussion of realistic expectations with patient and family regarding modest benefits 1

Expected Benefits and Limitations

Donepezil provides modest, not dramatic, improvements: 1, 10

• Only 20-35% of patients show clinically meaningful response (≥4-point improvement on cognitive scales) 1, 10
• Average improvement equals approximately 6-12 months of delayed decline 1
• Benefits include small improvements in cognition and global function, but effects on quality of life are inconsistent 10
• Does not cure or stop disease progression—all patients continue to decline over time 5

Dosing and Monitoring

If Alzheimer's disease is confirmed and treatment is initiated:

• Start at 5 mg once daily (taken with or without food) 1, 5
• Increase to 10 mg daily after 4-6 weeks if tolerated 1, 5
• Common side effects: nausea, diarrhea, vomiting (dose-related, gastrointestinal) 1, 5
• Monitor for: bradycardia, syncope, gastrointestinal bleeding (especially with NSAIDs), and worsening of anxiety initially 1, 5

Special Considerations for This Patient

Anxiety Management

The patient's anxiety requires concurrent attention:

• Anxiety can worsen cognitive test performance and subjective cognitive complaints 7
• Donepezil may initially increase agitation in some patients, though this typically subsides after several weeks 1
• Consider whether anxiety treatment (cognitive behavioral therapy, anxiolytics if appropriate) might improve cognitive symptoms before attributing all impairment to neurodegenerative disease 7

Avoiding Premature Treatment

Starting donepezil before establishing diagnosis carries risks:

• Inappropriate treatment if cognitive impairment is due to depression, anxiety, medication effects, or other reversible causes 6
• False reassurance that treatment is addressing the problem when underlying etiology remains unidentified 2
• Unnecessary side effects (gastrointestinal symptoms, bradycardia) without confirmed indication 5
• Delayed appropriate intervention for non-Alzheimer's conditions requiring different management 9

Practical Next Steps

1. Refer to memory clinic immediately for comprehensive neuropsychological evaluation 8
2. Refer to neurology for structural imaging and exclusion of reversible causes 1
3. Optimize anxiety management while awaiting specialty evaluation 7
4. Reassess medication list for anticholinergic or sedating medications that may impair cognition 6
5. Defer donepezil initiation until diagnosis is confirmed and severity is established 1, 2